Lenovo Launches GPU Advanced Services to Help Boost AI Workload Performance by Up to 30%
30.9.2025 16:00:00 EEST | Business Wire | Press release
With GPU demand outpacing enterprise deployment capacity, Lenovo today launched GPU Advanced Services to help customers boost workload performance by up to 30% and accelerate AI adoption.1 Enterprises can achieve these gains through optimized GPU deployment and tuning delivered by Lenovo experts, based on internal performance evaluations. For businesses, that means faster time-to-market for AI innovation and reduced infrastructure costs by avoiding underutilized GPUs.
“Enterprises are moving rapidly to operationalize AI, but many still struggle with the complexity of GPU infrastructure deployment,” said Steven Dickens, CEO and Principal Analyst of HyperFRAME Research. “Lenovo’s approach addresses this challenge by helping IT teams deploy faster, optimize performance, and scale confidently, which is exactly what the market needs as AI use cases become mainstream.”
As AI adoption surges, enterprises need scalable GPU infrastructure to support high-performance workloads. Lenovo GPU Advanced Services provide guided support to help enterprises design, deploy, and operate GPU-based systems efficiently. Taking a services-first approach, Lenovo enables enterprises to maximize existing investments and scale AI without being locked into proprietary stacks.
"With certified experts and deep platform integration, Lenovo helps enterprises deploy GPU infrastructure faster and run workloads more reliably, reducing risk and unlocking the full potential of their AI investments,” said Linda Yao, VP and General Manager, Hybrid Cloud & AI Solutions, Lenovo.
GPU Advanced Services align with validated Lenovo Hybrid AI Advantage™ solutions such as the Lenovo Hybrid AI 285 platform, enabling scalable deployment from a single node to multi-nodes with customizable AI software stack and services. Designed for high-performance workloads such as generative AI, real-time video processing, and content creation, these services address critical gaps in in-house expertise, infrastructure complexity, and performance tuning.
GPU Advanced Services: Flexible Options for Every Stage
GPU Advanced Services includes three modular options that can be purchased individually or combined, giving enterprises access to Lenovo experts at the stage that best fits their GPU adoption journey and avoiding a one-size-fits-all bundle.
- GPU Plan & Design Services– For organizations just beginning their AI journey, this service provides workload assessment, solution sizing, technology selection, and architecture planning to establish the right foundation.
- GPU Implementation Services – For teams ready to deploy, Lenovo experts deliver architecture documentation, stack configuration, deployment guidance, and knowledge transfer so systems are set up correctly and efficiently.
- GPU Managed Services – For enterprises running production AI, this service delivers ongoing optimization, updates, and recovery support, including patching and compliance, across hybrid and on-premises GPU environments.
Enterprises can accelerate their AI journey with Lenovo AI Fast Start, rapidly identifying and validating use cases before scaling confidently into production with GPU Advanced Services.
Proven Impact in Key Industries
Lenovo GPU Advanced Services ease the load on IT teams by streamlining deployment and creating a faster, lower-risk path from pilot to production. The services are designed to address challenges common across industries where AI is transforming operations:
- Healthcare – AI-assisted diagnostics with real-time insights help improve the speed and accuracy of patient care.
- Automotive – Managed services can help optimize edge AI models that power autonomous and connected vehicle systems.
- Media and Entertainment – GPU tuning can enhance real-time rendering and content production workflows, enabling creators to deliver richer experiences more efficiently.
- Cirrascale Cloud Services – Cut GPU deployment time by more than 40% with Lenovo expertise, accelerating AI innovation across customer environments.
A Proven Track Record in High-Performance GPU Solutions
Lenovo GPU Advanced Services offer flexible engagement backed by proven expertise in optimizing GPU infrastructure for performance and scalability. Built on Lenovo ThinkSystem and High-Performance Compute platforms, these services sit on top of GPU-rich Lenovo systems, ensuring customers maximize their hardware investments without being locked into a single platform.
Lenovo also brings unmatched leadership in advanced computing, ranked the #1 supercomputer provider for seven consecutive years2, #1 in x86 server reliability, and among the top in security.3 This trusted foundation ensures enterprises can scale AI infrastructure with confidence.
Discover how Lenovo GPU Advanced Services can help enterprises simplify management and scale AI with confidence at: http://lenovo.com/us/en/Solutions/Hybrid_Cloud_Services/GPU_Advanced_Services.
About Lenovo
Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
[1] Based on Lenovo internal performance evaluations of optimized GPU deployment and tuning.
[2] Supercomputing leadership — Lenovo remains the world’s #1 supercomputer provider by number of systems on the June 2025 TOP500 list. See TOP500 list statistics and vendor share; Lenovo also reiterated #1 status at ISC 2025.
[3] x86 server reliability & security — Independent ITIC studies report Lenovo ThinkSystem x86 servers with the best uptime for 11 straight years (latest report referenced February 2025) and among the most secure platforms in ITIC’s 2025 server security survey. See LenovoPress ITIC summary and coverage of the 2025 ITIC security survey; additional 2024 survey recap also confirms leadership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930144708/en/
Contacts
Zeno Group for Lenovo: lenovossg@zenogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom